Literature DB >> 32211773

Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function.

Jakob Albrethsen1,2, Trine Holm Johannsen1,2, Niels Jørgensen1,2, Hanne Frederiksen1,2, Henriette P Sennels3, Henrik Loevendahl Jørgensen3, Jan Fahrenkrug3, Jørgen Holm Petersen1,4, Allan Linneberg5,6, Loa Nordkap1,2, Anne Kirstine Bang1,2, Anna-Maria Andersson1,2, Anders Juul1,2,6.   

Abstract

BACKGROUND: The peptide hormone insulin-like factor 3 (INSL3) is a marker for Leydig cell function and the clinical use of serum INSL3 measurements has been suggested by several groups. AIM: (1) To establish a reference range for liquid chromatography-tandem mass spectrometry (LC-MS/MS) of serum INSL3 in healthy boys and men; and (2) to compare the associations of serum INSL3 and testosterone (T) to pubertal stage, lifestyle factors, diurnal variation, body composition, and human chorionic gonadotropin (hCG) stimulation.
RESULTS: In a reference range based on LC-MS/MS analysis of serum from 1073 boys and men, INSL3 increased from levels close to the detection limit (0.03 µg/L) in prepubertal boys to a maximum mean level of 1.3 µg/L (95% CI, 0.9-2.7) in young men (19-40 years of age) and decreased slightly in older men (0.1 µg/L per decade). Serum T, but not INSL3, was associated with body mass index or body fat percentage and with alcohol consumption. Smoking was positively associated with serum T, but negatively associated with INSL3. There were significant diurnal variations in both INSL3 and T in men (P < 0.001), but serum INSL3 varied substantially less, compared with serum T (± 11% vs ± 26%). Mean serum INSL3 increased after hCG stimulation, but less than T (+ 17% vs + 53%). In both healthy men and in patients suspected of testicular failure, baseline serum INSL3 was more closely associated to the hCG-induced increase in serum T than baseline T itself.
CONCLUSION: Measurement of serum INSL3 by LC-MS/MS has promise as a marker of testicular disorders. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  INSL3; LC-MS/MS; Leydig cell; diurnal variation; normal range; testosterone

Mesh:

Substances:

Year:  2020        PMID: 32211773     DOI: 10.1210/clinem/dgaa145

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.

Authors:  A Nordenström; S F Ahmed; E van den Akker; J Blair; M Bonomi; C Brachet; L H A Broersen; H L Claahsen-van der Grinten; A B Dessens; A Gawlik; C H Gravholt; A Juul; C Krausz; T Raivio; A Smyth; P Touraine; D Vitali; O M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

2.  Serum Concentrations and Gonadal Expression of INSL3 in Eighteen Males With 45,X/46,XY Mosaicism.

Authors:  Marie Lindhardt Ljubicic; Anne Jørgensen; Lise Aksglaede; John Erik Nielsen; Jakob Albrethsen; Anders Juul; Trine Holm Johannsen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-10       Impact factor: 5.555

3.  Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort.

Authors:  Ravinder Anand-Ivell; Kee Heng; Katie Severn; Leen Antonio; Gyorgy Bartfai; Felipe F Casanueva; Ilpo T Huhtaniemi; Aleksander Giwercman; Mario Maggi; Terence W O'Neill; Margus Punab; Giulia Rastrelli; Jolanta Slowikowska-Hilczer; Jos Tournoy; Dirk Vanderschueren; Frederick C W Wu; Richard Ivell
Journal:  Andrology       Date:  2022-07-11       Impact factor: 4.456

4.  Mass Spectrometry Supports That the Structure of Circulating Human Insulin-Like Factor 3 Is a Heterodimer.

Authors:  Jakob Albrethsen; Anders Juul; Anna-Maria Andersson
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-28       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.